LB Pharmaceuticals Inc (LBRX)
NASDAQ: LBRX · Real-Time Price · USD
47.78
+0.68 (1.44%)
Sep 2, 2026, 9:54 AM EDT - Market open
LB Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 283.11 | 250.17 | 22.98 | 14.98 | 21.4 |
Short-Term Investments | 44.68 | 45.04 | 5.02 | 28.31 | - |
Cash & Short-Term Investments | 327.79 | 295.21 | 28 | 43.29 | 21.4 |
Cash Growth | 2204.32% | 954.37% | -35.32% | 102.26% | - |
Prepaid Expenses | 4.74 | 2.46 | 0.46 | 2.34 | 0.08 |
Other Current Assets | 22.77 | 10.76 | 0.42 | 0.01 | 0.01 |
Total Current Assets | 355.3 | 308.43 | 28.88 | 45.63 | 21.49 |
Property, Plant & Equipment | 5.61 | 3.73 | 4.16 | 0.02 | 0 |
Other Long-Term Assets | 0.78 | 0.77 | 0.5 | - | - |
Total Assets | 361.69 | 312.93 | 33.53 | 45.66 | 21.49 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 3.49 | 2.13 | 2.32 | 1.39 | 0.16 |
Accrued Expenses | 19.23 | 4.59 | 5.3 | 1.22 | 0.31 |
Current Portion of Leases | 0.84 | 0.73 | 0.49 | - | - |
Total Current Liabilities | 23.56 | 7.44 | 8.11 | 2.61 | 0.47 |
Long-Term Debt | - | - | - | - | 24.15 |
Long-Term Leases | 4.37 | 2.84 | 3.22 | - | - |
Other Long-Term Liabilities | 1.41 | 1.34 | 2.5 | 1.56 | 18.49 |
Total Liabilities | 29.35 | 11.62 | 13.83 | 4.16 | 43.11 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 532.34 | 430.67 | 9.66 | 6.47 | 6.13 |
Retained Earnings | -200.19 | -129.53 | -104.32 | -41.22 | -34.95 |
Comprehensive Income & Other | 0.19 | 0.17 | 0.11 | 0.27 | - |
Total Common Equity | 332.35 | 301.31 | -94.55 | -34.47 | -28.81 |
Shareholders' Equity | 332.35 | 301.31 | 19.71 | 41.49 | -21.62 |
Total Liabilities & Equity | 361.69 | 312.93 | 33.53 | 45.66 | 21.49 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 5.22 | 3.57 | 3.7 | - | 24.15 |
Net Cash (Debt) | 322.57 | 291.64 | 24.3 | 43.29 | -2.74 |
Net Cash Growth | 2982.69% | 1100.38% | -43.88% | - | - |
Net Cash Per Share | 14.36 | 36.25 | 67.82 | 173.44 | -11.87 |
Filing Date Shares Outstanding | 32.26 | 28.67 | 0.25 | 0.25 | 0.23 |
Total Common Shares Outstanding | 28.68 | 25.3 | 0.25 | 0.25 | 0.23 |
Working Capital | 331.74 | 300.99 | 20.77 | 43.03 | 21.02 |
Book Value Per Share | 11.59 | 11.91 | -375.53 | -138.11 | -124.68 |
Tangible Book Value | 332.35 | 301.31 | -94.55 | -34.47 | -28.81 |
Tangible Book Value Per Share | 11.59 | 11.91 | -375.53 | -138.11 | -124.68 |
Machinery | 0.82 | 0.51 | 0.47 | 0.03 | 0.01 |
Leasehold Improvements | 1.98 | 1.49 | 1.49 | - | - |